Virtune AB (Publ) ("Virtune") has completed the monthly rebalancing for April 2024 of its Virtune Crypto Top 10 Index ETP, the first crypto index ETP in the Nordics.
Stockholm, 2nd of May 2024 - Today Virtune announces that it has finalized its monthly rebalancing for Virtune Crypto Top 10 Index ETP where several new cryptocurrencies including Solana, XRP and Cardano are being added.
The product is listed on Nasdaq Stockholm for both the SEK-denominated (ISIN code SE0020052207, ticker name VIR10SEK) and the EUR-denominated (ISIN code SE0020052215, ticker name VIR10EUR) ETP.
In addition to the Virtune Crypto Top 10 Index ETP, Virtune's product portfolio includes Virtune Staked Solana ETP, Virtune Staked Polygon ETP, Virtune Bitcoin ETP, Virtune Staked Ethereum ETP, Virtune Chainlink ETP, Virtune Staked Polkadot ETP, and Virtune Arbitrum ETP.
Index allocation as of 30th of April (before rebalancing):
Bitcoin: 41.47%
Ethereum: 41.65%
Polkadot: 4.63%
Chainlink: 4.01%
Litecoin: 2.90%
Uniswap: 2.31%
Stellar: 1.59%
Arbitrum: 1.46%
Index allocation as of 30th of April (after rebalancing):
Bitcoin : 40.00%
Ethereum: 40.00%
Solana: 8.23%
XRP: 3.58%
Cardano : 2.12%
Avalanche: 1.72%
Polkadot: 1.24%
Bitcoin Cash 1.19%
Chainlink: 1.06%
Polygon: 0.86%
As part of this month's rebalancing, new crypto assets have been added to the index. The newly added crypto assets are Solana, Cardano, Avalanche, Polygon, XRP, and Bitcoin Cash. Meanwhile, the existing crypto assets being excluded are Uniswap, Litecoin, Arbitrum, and Stellar. Virtune Crypto Top 10 Index ETP SEK outcome for April was -12.19%.
The rebalancing is carried out according to the index that the ETP tracks, the Virtune Vinter Crypto Top 10 Index, and this is the twelfth rebalancing since the product was listed on May 15th 2023. The purpose of the monthly rebalancing is to ensure that the ETP always reflects the current market conditions and to effectively absorb volatility in the cryptocurrency market.
In April, the crypto market experienced a pullback, with Bitcoin undergoing a -14.7% decrease following seven months of growth. Additionally, several altcoins also saw significant declines during the month.
The performance of the cryptocurrencies included in Virtune Crypto Top 10 Index ETP in April:
Uniswap -45.7%
Arbitrum -38.6%
Polkadot -33.4%
Chainlink -31.5%
Litecoin -24.3%
Stellar -23.9%
Ethereum -17.2%
Bitcoin -14.7%
Virtune's crypto index ETP is the first of its kind in the Nordic region. The ETP includes up to 10 leading cryptocurrencies that are part of the Nasdaq Crypto Index, based on their total market value, with a maximum weight of 40% per cryptocurrency to promote diversification. This allows investors to benefit from broad exposure to the cryptocurrency market without being heavily concentrated in any single cryptocurrency.
If you, as an (institutional) investor, are interested in meeting Virtune to discuss the possibilities with our ETPs for your asset management/discretionary asset management offering, to learn more about Virtune and/or the company's ETPs, please do not hesitate to contact us at hello@virtune.com.
You can also read more about Virtune and our ETPs on www.virtune.com and register your email address on our website to subscribe to our newsletters that covers updates on Virtune's upcoming ETP launches and other news related to digital assets.
Press contact
Christopher Kock, CEO Virtune AB (Publ)
Christopher@virtune.com
+46 70 073 45 64
Virtune with its headquarters in Stockholm is a fully regulated Swedish digital asset manager and issuer of crypto exchange traded products on regulated European exchanges.
With regulatory compliance, strategic collaborations with industry leaders and our proficient team, we empower investors on a global level to access innovative and sophisticated investment products that are aligned with the evolving landscape of the global crypto market.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Constellation Brands to Present at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 202416.5.2024 22:30:20 CEST | Press release
VICTOR, N.Y., May 16, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 2024 in New York, NY. The presentation is scheduled to begin at 2:30 p.m. EDT and is expected to cover the company’s strategic business initiatives, financial metrics, and operating performance, as well as outlook for the future. A live, listen-only webcast of the presentation will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the presentation begins, financial information discussed in the presentation, and a reconciliation of reported GAAP financial measures with comparable and other non-GAAP financial measures, will also be available
DBV Technologies Announces Results of its 2024 Combined General Meeting16.5.2024 22:30:00 CEST | Press release
Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by the Board of Directors. These resolutions and their results are posted on the Investors/Annual General Meetings section of the Company’s website: https://dbv-technologies.com/events/2024-annual-general-meeting/. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with sign
Clean Motion AB delårsredogörelse för januari-mars 202416.5.2024 22:10:00 CEST | Pressemelding
Elfordonstillverkaren Clean Motion AB presenterar sin delårsrapport för januari-mars 2024. Bolaget redovisar en försäljning på 38 (45) TSEK och ett rörelseresultat exklusive avskrivningar (EBITDA) på -2 949 (-1 825) TSEK. Bolaget meddelar även att ett licensavtal är tecknat för tillverkning av Zbee i Indien samt att deras nya produktionslokal för EVIG i Jonsered nu är godkänd. Sofia Haby, VD kommenterar; ”Vi har jobbat intensivt under kvartalet med både typgodkännande-processen och flytt till nya lokaler. Kvartalet har präglats av de förseningar som vi drabbats av med vårt typgodkännande, vilket förhindrat försäljning i Europa. Jag kan nu med glädje meddela att det mest kritiska testet blev godkänt igår kväll! Under de senaste månaderna har vi jobbat med att färdigställa vår nya produktionslokal i Jonsered. Jag är övertygad om att vi genom att samla alla resurser under ett tak, kommer att åstadkomma stora effektivitetsförbättringar. Teamet har arbetat dedikerat med att säkerställa en s
Galapagos creates new subscription right plans16.5.2024 22:01:00 CEST | Press release
Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 16 May 2024, the Board of Directors of Galapagos approved “Subscription Right Plan 2024 BE”, intended for members of personnel of the company, “Subscription Right Plan 2024 RMV,” intended for the employees of its French subsidiary, Galapagos SASU, and “Subscription Right Plan 2024 ROW”, primarily intended for the employees of its other non-Belgian subsidiaries, within the framework of the authorized capital. Under these subscription right plans, 1,614,000 subscription rights were created, subject to acceptances, and offered to the beneficiaries of the plans. The subscription rights have an exercise term of eight years as of the date of the offer and have an exercise price of €
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH16.5.2024 22:00:00 CEST | Press release
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, has been without clinical symptoms throughout the period of observation and has fully recovered.The DMC review confirms the good safety profile of lanifibranor. Daix (France), Long Island City (New York, United States), May 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepa